Lundbeck Names Tarek Samad as New Head of R&D Amid Leadership Transition
Event summary
- Tarek Samad appointed EVP, Head of R&D at Lundbeck effective September 1, 2026.
- Succeeds Johan Luthman, who retires after seven years leading R&D transformation.
- Samad previously served as Senior Vice President, Global Head of Research and Corporate Patents since 2021.
- Luthman's tenure saw major restructuring, new drug modality platforms, and first-in-class pipeline development.
The big picture
Lundbeck's leadership change in R&D comes amid a broader industry shift toward neuroscience innovation. The appointment reflects Lundbeck's focus on internal talent development to maintain its position as a leader in brain health treatments. Samad's background in both academia and industry suggests a continued emphasis on scientific excellence and strategic partnerships.
What we're watching
- Pipeline Momentum
- Whether Samad can sustain the innovative pipeline momentum established under Luthman.
- Strategic Partnerships
- How Samad will leverage his experience with Immunitas Therapeutics, Sanofi, and Pfizer to strengthen Lundbeck's research collaborations.
- Execution Risk
- The pace at which the transition period ensures continuity across key strategic and scientific priorities.